600 patients66,869 observations120 daysLIVE

Patient P-01328

Synthetic patientNBL-101 · Day 102 · 55–64 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
92%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 44 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 46 SC-12 recommendedSupportive Compound SC-12
  4. Day 47 Patient acceptedStarted SC-12 in the companion
  5. Day 53 No meaningful changeSupportive Compound SC-12
  6. Day 56 GI-04 recommendedGI Support Protocol GI-04
  7. Day 57 Patient declinedNot now

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days
  • Toxicity-4
  • Treatment adherence-3
  • Nutritional resilience+2

What helped?

  • Supportive Compound SC-12Day 46
    Result: no meaningful change
  • GI Support Protocol GI-04Day 56
    Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
64.5/100
worsening · +5.2 vs previous 14 d
Toxicity
Blood
44.7/100
worsening · +2.6 vs previous 14 d
Sleep quality
Wearable
31.4/100
stable · +0.7 vs previous 14 d
Energy level
Daily log
2.5/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
6.6/10
worsening · +0.4 vs previous 14 d
Steps
Wearable
3,914
worsening · -567 vs previous 14 d
Adherence
Companion
46.6 %
worsening · -5.8 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 28 from the failing basin, 65 from restoration.

Would help
  • GI-04 GI Support Protocol
    73% improved among 124 similar · onset 8 d · confidence 97%
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 78%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 78%
Would not help
  • SC-12 Supportive Compound
    already tried, no meaningful change
  • Keep fat low
    GI +6.5 next day on high-intake days · n 29
  • Keep histamine low
    GI +5.7 next day on high-intake days · n 24
  • Keep simple carbs low
    GI +5.3 next day on high-intake days · n 22
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +6.5detractor · 95%
  • Histamine load
    +5.7detractor · 95%
  • Simple carbohydrates
    +5.3detractor · 95%
  • Insoluble fibre
    +3.7detractor · 77%
  • Alcohol
    +3detractor · 70%
  • Spicy / capsaicin
    +2.7no signal · 45%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 65 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 44/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 58
  • Autonomic recovery 45
    • WearableResting HR 73 bpm
    • Wearable3,914 steps/day
  • Drug metabolism and exposure 20
    • BloodToxicity index 45
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.7 · butyrate capacity 44/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
49 ms
Sleep
6.9 h
Steps
3,391
Resting HR
74 bpm
Daily log: GI score 65, nutritional resilience 29, adherence 47.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0160419%S0171
P-0138619%S1370
P-0135219%S2070
P-0175019%S1669
P-0169924%S04GI-04improved69
P-0150820%S1868
P-0175419%S1468
P-0150920%S1768
P-0187520%S1167
P-0181719%S1467
P-0187724%S01CR-01improved67
P-0162920%S1966